Intralesional EBV-DNA load as marker of prognosis for nasopharyngeal cancer.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
28 10 2019
Historique:
received: 07 06 2019
accepted: 07 10 2019
entrez: 30 10 2019
pubmed: 30 10 2019
medline: 29 10 2020
Statut: epublish

Résumé

Nasopharyngeal cancer (NPC) is associated with the Epstein-Barr virus (EBV). The clinical presentation and prognosis of NPC is well described, but not in relation to intralesional EBV-DNA load. In a retrospective design, 48 patients with NPC were examined. Patient history was re-evaluated, and diagnostic biopsies were re-examined. Furthermore, intralesional EBV-DNA was quantitated and HPV status determined. Cancer stage, disease-free survival (DFS), and overall survival (OS) were assessed. Of the 48 patients, 36 (75%) patients featured lesions that were positive for EBER (Epstein-Barr virus-encoded small RNA) and 40 (83%) were positive for EBV-DNA. Seven patients (15%) were HPV positive. The levels of EBV-DNA ranged from 0.0005 to 94617 copies/cell. An EBV-DNA load of more than 70 copies/cell was associated with a prolonged DFS for EBV-DNA positive patients treated with curative intent (p = 0.046). In conclusion, the EBV-DNA load in NPC lesions appears to vary greatly. For patients with EBV-DNA positive NPC treated with curative intent, an EBV-DNA load of more than 70 copies/cell is associated with a better outcome in terms of 7-year DFS.

Identifiants

pubmed: 31659192
doi: 10.1038/s41598-019-51767-9
pii: 10.1038/s41598-019-51767-9
pmc: PMC6817933
doi:

Substances chimiques

Biomarkers, Tumor 0
DNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15432

Références

Clin Cancer Res. 2002 Aug;8(8):2612-9
pubmed: 12171892
Head Neck. 2019 Feb;41(2):349-357
pubmed: 30549170
Acta Otolaryngol. 2008 May;128(5):583-9
pubmed: 18421616
Head Neck. 2018 Jul;40(7):1515-1523
pubmed: 29522272
J Natl Cancer Inst. 1970 Jan;44(1):225-31
pubmed: 11515035
ScientificWorldJournal. 2017;2017:2721367
pubmed: 28421207
Curr Opin Virol. 2015 Dec;15:75-9
pubmed: 26322696
Asian Pac J Cancer Prev. ;18(2):327-331
pubmed: 28345327
Pathol Res Pract. 2016 Nov;212(11):1021-1026
pubmed: 27640103
Head Neck. 2014 May;36(5):709-14
pubmed: 23616441
Auris Nasus Larynx. 2017 Jun;44(3):327-332
pubmed: 27499435
Mol Cancer Res. 2017 Dec;15(12):1722-1732
pubmed: 28851814
Head Neck. 2014 Apr;36(4):511-6
pubmed: 23780921
Arch Pathol Lab Med. 2018 May;142(5):559-597
pubmed: 29251996
Oral Oncol. 2014 May;50(5):326-9
pubmed: 24486206
Lancet. 1964 Mar 28;1(7335):702-3
pubmed: 14107961
Clin Cancer Res. 2013 Apr 15;19(8):2175-86
pubmed: 23493345
Oncotarget. 2017 Jul 18;8(29):47780-47789
pubmed: 28562354
Oral Oncol. 2014 Jun;50(6):527-38
pubmed: 24440146
N Engl J Med. 2017 Aug 10;377(6):513-522
pubmed: 28792880
Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):580-8
pubmed: 24521676
Cancer. 2013 Mar 1;119(5):963-70
pubmed: 23065693
Cancer. 2004 Apr 1;100(7):1429-37
pubmed: 15042677
Nat New Biol. 1973 Aug 22;244(138):245-7
pubmed: 4353684
Head Neck. 2010 May;32(5):562-7
pubmed: 19757421
Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):
pubmed: 28893940
Cancer. 1998 Apr 15;82(8):1449-53
pubmed: 9554519
Head Neck. 2016 Apr;38 Suppl 1:E1459-66
pubmed: 26560893
Cancer Res. 1999 Nov 1;59(21):5452-5
pubmed: 10554016
J Clin Microbiol. 2011 Oct;49(10):3560-7
pubmed: 21832015
Nat Genet. 2014 Aug;46(8):866-71
pubmed: 24952746
Am J Otolaryngol. 2018 Nov - Dec;39(6):764-770
pubmed: 30029797
J Clin Microbiol. 2009 Mar;47(3):541-6
pubmed: 19144817
Cancer. 2018 Feb 1;124(3):530-536
pubmed: 29072774
Clin Cancer Res. 2018 Feb 1;24(3):634-647
pubmed: 29018052
Semin Cancer Biol. 2012 Apr;22(2):117-26
pubmed: 22311401
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77
pubmed: 17035381
Sex Transm Dis. 2013 Feb;40(2):123-9
pubmed: 23324975
Head Neck. 2018 Apr;40(4):696-706
pubmed: 29323765
Cancer Sci. 2015 Sep;106(9):1196-201
pubmed: 26082292
Laryngoscope. 2010 Oct;120(10):1990-7
pubmed: 20824783
Anticancer Res. 2004 Nov-Dec;24(6):4059-66
pubmed: 15736452
Lancet. 2005 Jun 11-17;365(9476):2041-54
pubmed: 15950718
Int J Cancer. 1979 Jun 15;23(6):762-7
pubmed: 223991
Lancet. 2016 Mar 5;387(10022):1012-1024
pubmed: 26321262
J Gen Virol. 2016 Nov;97(11):2949-2956
pubmed: 27667722
Cancer. 2015 Aug 15;121(16):2671-3
pubmed: 25946565

Auteurs

Johan S Nilsson (JS)

Department of ORL, Head & Neck Surgery, Skåne University Hospital, Lund, Sweden. johan.s.nilsson@skane.se.
Department of Clinical Sciences, Lund University, Lund, Sweden. johan.s.nilsson@skane.se.

Ola Forslund (O)

Department of Laboratory Medicine, Medical Microbiology, Lund University, Lund, Sweden.

Fredrik C Andersson (FC)

Department of Laboratory Medicine, Clinical Genetics and Pathology, Skåne University Hospital, Lund, Sweden.

Malin Lindstedt (M)

Department of Immunotechnology, Lund University, Lund, Sweden.

Lennart Greiff (L)

Department of ORL, Head & Neck Surgery, Skåne University Hospital, Lund, Sweden.
Department of Clinical Sciences, Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH